Medivir: Marketing Authorization Application for Simeprevir to the EMA for the treatment of patients with genotype 1 and genotype 4 hepatitis C is now filed

Medivir: Marketing Authorization Application for Simeprevir to the EMA for the treatment of patients with genotype 1 and genotype 4 hepatitis C is now filed

HUDDINGE, Sweden --(Business Wire)--

Regulatory News:

Medivir AB (OMX: MVIR) (STO:MVIR-B) today announces that Janssen-Cilag International NV (Janssen) today has submitted a Marketing Authorization Application to the European Medicines Agency (EMA seeking approval for simeprevir (TMC435).

"The filing of simeprevir in Europe represents the third filing in major regions in the last two months. It shows the commitment and speed with which our partner Janssen acts in the process of bringing new hepatitis C treatments to the market", said Maris Hartmanis, CEO of Medivir AB.

The regulatory submission for simeprevir is supported by data from three phase III studies in patients with genotype 1 hepatitis C: QUEST-1 and QUEST-2 in treatment-naïve patients, and PROMISE in patients who have relapsed after prior interferon-based treatment. The filing for the treatment of patients with the genotype 4 virus is based on phase II data and an ongoing phase III study.

Simeprevir is a new generation NS3/4A protease inhibitor, administered as a capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 and 4 chronic hepatitis C in adult patients. Genotype 1 i the most prevalent form of hepatitis C virus (HCV) worldwide.

For more information about Medivir AB, please visit the Company's website: www.medivir.com
This information was brought to you by Cision http://news.cision.com

Related-
March 29, 2013
Simeprevir (TMC435) - Janssen Submits New Drug Application to U.S. FDA

Feb 22 2013
Simeprevir (TMC435) Regulatory Application has now been filed in Japan for the treatment of genotype 1 hepatitis C patients